@article{Mudra_2020, title={THE TACTICS OF ANTIVIRAL THERAPY FOR CHRONIC VIRAL HEPATITIS B IN PREGNANT WOMEN}, url={http://journal.eu-jr.eu/ttism/article/view/1523}, DOI={10.21303/2585-663.2020.001478}, abstractNote={<p><strong>The aim of the study.</strong>Analysis of tactics of antiviral therapy for chronic viral hepatitis b in pregnant women.</p> <p><strong>Methods.&nbsp;</strong>Theoretical analysis of scientific literature; analysis and generalization. Statistics and comparisons. Classification of theoretical material and development of recommendations.</p> <p><strong>Research results.</strong>Today, there are about 2 billion people in the world ill with a chronic infection caused by the hepatitis B virus, 350 million of whom suffer from chronic hepatitis B, and most are asymptomatic carriers of the Australian antigen (HBsAg). Up to 50 % of all new cases of hepatitis B virus infection are due to vertical infection. Despite the lack of increase in viral load during pregnancy, alanine aminotransferase tends to increase in late pregnancy and in the postpartum period. A sharp drop in postpartum corticosteroids may create favourable conditions for hepatitis B virus activation. It is emphasized that the current treatment of hepatitis B virus includes the use of antiviral drugs, where Peg-IFN is absolutely contraindicated in pregnancy, lamivudine and entecavir are classified by the FDA as category C, and tenofovir and telbivudine are classified as category B. During pregnancy, it is recommended to use mainly category B drugs.</p> <p><strong>Conclusions.&nbsp;</strong>The use of antiviral therapy in combination with immunoprophylaxis of new-borns is the optimal strategy for implementation as a universal program, as the success of such an intervention can make a significant contribution to achieving the ultimate goal of global elimination of hepatitis B virus.</p&gt;}, journal={Technology transfer: innovative solutions in medicine}, author={Mudra, Yuliia}, year={2020}, month={Oct.}, pages={14-16} }